Fig. 3From: Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance studyKaplan–Meier plots of time-to-treatment failure in unmatched and matched patients. C20, 20 mg/m2 cabazitaxel; C25, 25 mg/m2 cabazitaxelBack to article page